Filing Flows › Interpace Biosciences (IDXG) › Q1 2025
Interpace Biosciences (IDXG) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 8, 2025
Interpace Biosciences (IDXG) reported revenue of $11.5M for the first quarter 2025 (Q1 2025), +13% from a year earlier and -7% from the quarter before. Operating margin was 15.9%, net earnings $1.6M (14.3% of revenue).
Interpace Biosciences, Q1 2025: revenue $11.5M (+13% year over year), operating margin 15.9%, net earnings $1.6M, operating cash flow $1.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $11.5M | -7% | +13% |
| Gross profit | $7.4M | -7% | +17% |
| Operating profit | $1.8M | -11% | +64% |
| Net earnings | $1.6M | -12% | +133% |
| Operating cash flow | $1.2M | +4% | — |
What changed
Revenue was $11.5M in Q1 2025, up 13% year over year and down 7% from the previous quarter.
Gross margin was 64.0%, up 2.0 points from a year earlier. Operating profit was $1.8M, a 15.9% margin (up 4.9 points year over year). Of the extra revenue versus a year earlier, 53% reached operating profit, above the 11% margin then. Operating expenses grew 7% against revenue growth of 13%. The fastest-growing cost line was Research & development (+29%). Net earnings were $1.6M, up 133% year over year. The effective tax rate was 1.1%.
Operating cash flow was $1.2M, 75% of net earnings. Non-cash charges added back $95K of depreciation and amortization and $15K of share-based compensation. Working capital and other items used $522K.
Questions
What was Interpace Biosciences' revenue in the first quarter 2025?
Interpace Biosciences (IDXG) reported revenue of $11.5M for the first quarter 2025 (Q1 2025), +13% from a year earlier and -7% from the quarter before.
Was Interpace Biosciences profitable in the first quarter 2025?
Operating profit was $1.8M (15.9% of revenue) and net earnings $1.6M.